Clinical Trial Update: A Study to Evaluate the Safety and Efficacy of Nivolumab Monotherapy and Nivolumab in Combination With Ipilimumab in Pediatric Participants With High Grade Primary Central Nervous System (CNS) Malignancies [Phase 2]

View source ↗

Summary

Phase 2 trial assessing nivolumab alone and in combination with ipilimumab in pediatric high-grade CNS malignancies has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• High-grade Central Nervous System Malignancies

Drugs mentioned

• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Various Advanced Cancer | Phase 2 | Status: COMPLETED | Results posted: 2021-04-01